U.S. cancer drug maker Medivation Inc has decided to explore a sale following a $9.3 billion acquisition offer from France's Sanofi SA and interest from other companies, people familiar with the matter said on Monday. Pfizer Inc and Amgen Inc are among the companies that have signed non-disclosure agreements with Medivation, which allow them to obtain confidential information about the company, the people said. The move comes less than two weeks after Sanofi made its approach public by publishing a letter to Medivation's chief executive David Hung that contained details of the offer.
See the rest here:
Exclusive: Medivation succumbs to pressure to explore sale – sources